Feature Channels:

Parkinson’s Disease

Add to Favorites Subscribe Share

GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations

GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) announced significant preclinical results for their Parkinson's disease ("PD") formulations from the midterm report for their preclinical study being performed by Dr. Lee Ellis of the National Research Council (NRC) in Halifax, Nova Scotia, CANADA.

Channels: Clinical Trials, Neuro, Parkinson’s Disease, Pharmaceuticals,

Released:
20-Dec-2019 10:25 AM EST
Georgetown_H_GUMC_blueRGB.jpg
  • Embargo expired:
    16-Dec-2019 11:00 AM EST

Nilotinib Appears Safe In Parkinson’s Trial; Drug Thought to Allow Dopamine Replenishment

Georgetown University Medical Center

A clinical trial investigating the repurposed cancer drug nilotinib in people with Parkinson’s disease finds that it is reasonably safe and well tolerated. Researchers also report finding an increase in dopamine, the chemical lost as a result of neuronal destruction, and a decrease in neurotoxic proteins in the brain among study participants. Finally, they say nilotinib, a tyrosine kinase inhibitor, potentially halts motor and non-motor decline.

Channels: All Journal News, Cancer, Clinical Trials, Parkinson’s Disease, Pharmaceuticals, JAMA,

Released:
12-Dec-2019 12:05 PM EST
Feature
Newswise: Why Doesn’t Deep-Brain Stimulation Work for Everyone?
  • Embargo expired:
    10-Dec-2019 11:00 AM EST

Why Doesn’t Deep-Brain Stimulation Work for Everyone?

Washington University in St. Louis

Researchers at Washington University School of Medicine in St. Louis have mapped nine functional networks in the deep-brain structures of 10 healthy people, an accomplishment that could lead to improvements in deep-brain stimulation therapy for severe cases of Parkinson’s disease and other neurological conditions.

Channels: Cell Biology, Neuro, Parkinson’s Disease, Staff Picks, All Journal News, Grant Funded News,

Released:
6-Dec-2019 4:05 PM EST
Research Results
Newswise: 218695_web.jpg

A new study reveals the function of corpora amylacea to remove brain waste substances

Universidad De Barcelona

An article published in Proceedings of the National Academy of Sciences (PNAS) describes a new pathway in the central nervous system to expel waste substances from the brain through the creation of corpora amylacea (CA), aggregates formed by glucose polymers amassing waste products.

Channels: Aging, All Journal News, Alzheimer's and Dementia, Neuro, Parkinson’s Disease, PNAS,

Released:
4-Dec-2019 12:05 PM EST
Expert Pitch
aan-logo.gif
  • Embargo expired:
    27-Nov-2019 4:00 PM EST

Beware of Swimming if You Use Deep Brain Stimulation for Parkinson’s

American Academy of Neurology (AAN)

Researchers have identified nine cases of people who lost their ability to swim after having a deep brain stimulation device implanted to control symptoms of Parkinson’s disease. The new research is published in the November 27, 2019, online issue of Neurology®, the medical journal of the American Academy of Neurology. All nine people had been good swimmers even after their Parkinson’s disease diagnosis. But once they had deep brain stimulation surgery, researchers found while other movement symptoms improved, their swimming skills deteriorated.

Channels: All Journal News, Neuro, Parkinson’s Disease, Neurology (journal),

Released:
22-Nov-2019 11:05 PM EST
Research Results
Newswise: Stem Cells Don't Take the Day Off on Thanksgiving

Stem Cells Don't Take the Day Off on Thanksgiving

Cedars-Sinai

While most of us are enjoying the traditional turkey and pumpkin pie on Thanksgiving Day, employees at Cedars-Sinai will be hand-feeding stem cells their special daily formula, carefully monitoring the incubator temperatures and caring for the cells that may become part of important research that could one day lead to treatments for diseases that have plagued humans for years.

Channels: Alzheimer's and Dementia, Cancer, Diabetes, Neuro, Parkinson’s Disease,

Released:
22-Nov-2019 7:05 PM EST
Research Results
coriell_logo_CMYK.jpg

NINDS Awards Coriell Institute for Medical Research $7.7 Million Contract

Coriell Institute for Medical Research

The five-year award will support the NINDS Human Genetics Resource Center, a collection of biological samples and corresponding demographic, clinical, and genetic data made available to qualified researchers around the world. This repository includes samples from subjects with various diseases – such as cerebrovascular disease, dystonia, epilepsy, motor neuron disease, parkinsonism, and Tourette Syndrome.

Channels: All Journal News, Epilepsy, Genetics, Neuro, Parkinson’s Disease, Grant Funded News,

Released:
21-Nov-2019 8:00 AM EST
Feature

A Game-Changing Test for Prion, Alzheimer’s, and Parkinson’s Diseases is on the Horizon

Lawrence Berkeley National Laboratory

A new test agent can easily and efficiently detect the misfolded protein aggregates that cause devastating neurological diseases in blood samples. The technology could lead to early diagnosis of prion, Alzheimer's, and Parkinson's diseases for the first time.

Channels: All Journal News, Alzheimer's and Dementia, Materials Science, Parkinson’s Disease, PLOS ONE, DOE Science News,

Released:
6-Nov-2019 11:00 AM EST
Research Results


0.81335